AVDL Avadel Pharma: Multiplikator Forward P/S

Avadel Pharmaceuticals (AVDL) aims to reshape the narcolepsy therapy market by introducing the innovative Lumryz to displace outdated treatment methods. The forward price-to-sales ratio confirms this trajectory, with the parameter reaching 8.50. Niche dominance is secured by a unique nightly dosing regimen, while rapid sales growth drives the drug's current commercial success in the US.

AVDL (avadel.com) riwayat Rasio rega marang prakiraan pendapatan saka 13.08.2023 nganti 28.02.2026

Avadel Pharmaceuticals - rincian analitis lan metrik utama (AVDL)

- rega pasar lan target rega analis:

Bagan rega avadel.com|AVDL - Rata-rata rega prakiraan

- data kapitalisasi saham perusahaan:

Kapitalisasi pasar Avadel Pharmaceuticals|AVDL - Nilai Perusahaan

- statistik nilai buku emiten:

Nilai Akuntansi saben Saham Avadel Pharmaceuticals|AVDL - Nilai Buku Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku avadel.com|AVDL - Total Aset Perusahaan

- indikator beban kredit lan likuiditas emiten:

Total Utang marang Modal Avadel Pharmaceuticals|AVDL - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal Avadel Corp|AVDL - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Avadel Pharmaceuticals plc|AVDL - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Avadel Pharmaceuticals|Likuiditas cepet avadel.com

- indikator pendapatan resik lan kelipatan nilai:

AVDL - Bathi sawise pajeg|Proyeksi bathi mangsa ngarep Avadel Pharmaceuticals|AVDL - Nilai perusahaan marang bathi resik|Pangali Forward P/E Avadel Corp|AVDL - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Avadel Pharmaceuticals PLC|AVDL - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Avadel Pharmaceuticals|AVDL - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan avadel.com|AVDL - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Avadel Pharmaceuticals

- indikator pendapatan dodolan lan penghasilan bisnis:

AVDL - Dodolan perusahaan|Prakiraan volume dodolan avadel.com|AVDL - Rega marang dodolan|Multiplikator forward rega marang pendapatan Avadel Pharmaceuticals

Analisis wiwitan perusahaan:AVDL (Avadel Pharma)

The expansion of the drug Lumryz within the neuropsychiatry market directly impacts the market valuation of Avadel Pharmaceuticals (AVDL). The forward P/S ratio measures the business value relative to expected sales, revealing the company's hidden vulnerabilities to a potential takeover. This metric is calculated by dividing the current share price by the projected revenue for the following year. A decline in this ratio makes the asset attractive to a strategic buyer, yet it may signal internal issues.

Karo sapa Avadel Pharmaceuticals saingan

Rasio rega marang prakiraan pendapatan alkermes.com ALKS|atai Life Sciences Corp (ATAI) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|GH Research Group - Multiplikator Forward P/S|Mind Medicine (MNMD) - Multiplikator forward rega marang pendapatan|COMPASS Corp (CMPS) - Rasio rega marang prakiraan pendapatan|LBRX (LB Pharma) - Rasio rega marang prakiraan pendapatan|DRUG (Bright Minds Corp) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan VNDA (Vanda Pharmaceuticals Inc)|Multiplikator Forward P/S CYBN|ANRO - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan NRx Pharmaceuticals NRXP|Multiplikator Forward P/S Cingulate Inc. CING|SILO - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan CPHI (China Pharma Holdings, Inc.)|CMND: Multiplikator Forward P/S|Psyence Biomedical Ltd. - Rega forward marang dodolan|SPRC (SciSparc Ltd.) - Multiplikator Forward P/S|SEEL (Seelos Therapeutics, Inc.) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S VRPX|KRTX (Karuna) - Rega forward marang dodolan